English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Trastuzumab is a humanized monoclonal antibody approved for treatment of HER2 (human epidermal growth factor 2) positive breast cancer. Conjugation of trastuzumab offers a promising strategy of selective anticancer therapy. Trastuzumabemtansin is a new generation of cytotoxic drug conjugated antibody with higher tumour selectivity and less toxicity of emtansin. Conjugates of trastuzumab with bifunctional chelators (BFCs) for further radiolabelling are a step ahead in the field of radiopharmacy for therapy and imaging of aggressive HER2 positive cancers. The purpose of this study is characterization of integrity and secondary structure of antibody in already formulated lyophilized conjugates with p-SCN-Bn-DTPAand pSCN-Bn-1B4M-DTPAby applying SDS-PAGE electrophoresis and Raman spectroscopy. The results are positive and give an opportunity for further radiolabelling of freeze dried conjugates.

farmacia

ELECTROPHORESIS AND RAMAN SPECTROSCOPY CHARACTERIZATION OF INTEGRITY AND SECONDARY STRUCTURE OF p-SCN-Bn-DTPA- AND p-SCN-Bn-1B4M-DTPACONJUGATED TRASTUZUMAB